- $3.57bn
- $3.08bn
- $517.15m
Brief: Veracyte Provides Statement On Impact Of Events Surrounding Silicon Valley Bank
Veracyte Inc reports results for the quarter ended in December - Earnings Summary
Veracyte Inc expected to post a loss of 15 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Amgen, Equitable Holdings, Royal Caribbean
U.S. STOCKS ON THE MOVE-Organon, Veracyte, InfuSystem
Veracyte up on 2022 sales forecast raise
Veracyte Inc reports results for the quarter ended in September - Earnings Summary
Brief: Veracyte Announces Third Quarter 2022 Financial Results
Veracyte Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: New Data Presented At ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions In Men With Advanced Prostate Cancer
Brief: New Data Suggest Veracyte’S Envisia Genomic Classifier Can Help Predict Disease Progression In Interstitial Lung Disease Patients Treated With Combination Immunosuppressive Therapy
Brief: Veracyte Appoints Eliav Barr To Its Board Of Directors
Brief: Veracyte Announces Second Quarter 2022 Financial Results
Veracyte Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Veracyte Announces New Clinical Validation Data For Rna Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published In Thyroid
Brief: New Data Show Strong Performance Of Veracyte’S Afirma Gsc In Real-World Clinical Practice
Brief: Data Published In Annals Of Oncology Reinforce Clinical Utility Of Veracyte’S Decipher Prostate Genomic Classifier For Informing Treatment Of Men Experiencing Prostate Cancer Progression
Brief: Veracyte Announces That New Data Show Immunoscore IC Assay May Predict Patients Likely To Benefit From Addition Of Immunotherapy To Standard First-Line Therapy For Metastatic Colorectal Cancer
Brief: New Data To Be Shared At Asco 2022 Underscore Clinical Utility Of Decipher Prostate Genomic Classifier